CO₂ Value Europe submitted its response to the consultation on the future European Biotech Act, which will aim “at creating an enabling environment to make it easier to bring biotech products from the laboratory to the factory and then onto the market”.
In particular, our contribution is structured around two key asks:
🔵 CCU value chains involving biogenic captured carbon and/or biological conversions of captured carbon, known as BioCCU, should be part of the Biotech Act to increase circularity of production systems and reduce reliance on fossil resources.
🔵 Removing regulatory bottlenecks from the CCU value chain, helping Member States to support bioCCU value chains in their national strategies and developing market pull mechanisms for the introduction of bioCCU products in the market are essential elements for the development of this section of the biotech economy.
In current EU discussions, it is crucial that policymakers create synergies between technologies and do not create legislations in silos. CCU products can only become more competitive with an EU framework that considers and incentivises them – and excluding CCU from such initiatives would be a missed opportunity for building bridges between clean technologies, as well as leaving out untapped potential for moving away from fossil resources. The Biotech Act is an opportunity to advance considerably the development of bioCCU value chains and contribute to our climate and circularity targets.
Our full position can be found here.
